ENYO PHARMA

Their core work

ENYO Pharma is a French biotech SME specializing in drug discovery through systems biology and autophagy-based approaches. The company develops preclinical drug candidates by combining computational biology with experimental validation, focusing on understanding disease mechanisms at the cellular level. Their work spans from early-stage drug discovery pipelines to rapid drug repurposing for emerging infectious diseases, as demonstrated by their COVID-19 response involvement.

What they specialise in

How they've shifted over time

ENYO Pharma began with ambitious proprietary drug discovery, leading the MIMESIS project (2016-2018) as coordinator with substantial funding to build preclinical assets using systems biology. From 2017 onward, they deepened their expertise in autophagy — a specific cellular mechanism — through the DRIVE training network. By 2020, they pivoted this accumulated knowledge toward pandemic response, contributing drug repurposing capabilities to the large CARE consortium against COVID-19.

Moving from broad drug discovery toward specialized autophagy-based therapeutics and rapid drug repurposing for infectious diseases — a direction with strong future demand.

How they like to work

ENYO Pharma adapts its role to fit the project: they led their own drug discovery program (MIMESIS) as coordinator, joined an academic training network (DRIVE) as a partner, and contributed as a third party in the large-scale CARE pandemic consortium. Despite only three projects, they have connected with 74 unique partners across 15 countries, largely through the large CARE consortium. This suggests a company comfortable operating both independently and within very large research networks.

Through three projects, ENYO Pharma has built connections with 74 partners across 15 countries, primarily through the large CARE pandemic response consortium. Their network spans a broad European geography, reflecting the scale of the consortia they have joined rather than long-term repeat partnerships.

What sets them apart

ENYO Pharma combines computational systems biology with deep expertise in autophagy — a cellular recycling mechanism increasingly recognized as a drug target. This dual competency allows them to both discover new drug candidates and rapidly repurpose existing ones, as proven during the COVID-19 response. For consortium builders, they offer a rare profile: an SME with its own drug discovery platform that can also plug into large academic and clinical networks as a specialized contributor.

Highlights from their portfolio

• MIMESIS
  Their flagship project as coordinator with EUR 2.5M funding, building their proprietary systems biology drug discovery platform.
• CARE
  Part of the major European COVID-19 drug repurposing effort, demonstrating ability to contribute to rapid pandemic response at scale.
• DRIVE
  Training network that deepened their autophagy specialization, connecting them to the broader European autophagy research community.